行情

REPH

REPH

Recro Pharma
NASDAQ

实时行情|Nasdaq Last Sale

17.13
+0.12
+0.71%
交易中 14:58 12/10 EST
开盘
17.04
昨收
17.01
最高
17.36
最低
17.00
成交量
20.35万
成交额
--
52周最高
17.36
52周最低
4.957
市值
3.89亿
市盈率(TTM)
-7.3510
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

REPH 新闻

  • Spin-Off Expert Sees Healthy Gains for Recro Pharma
  • MoneyShow.5天前
  • The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug
  • Benzinga.6天前
  • The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
  • Benzinga.12/03 12:59
  • 美农场破产量飙升24%创6年新高 农业危机“在路上”?
  • 第一财经.12/03 09:53

更多

所属板块

生物技术和医学研究
+0.60%
制药与医学研究
+0.73%

热门股票

名称
价格
涨跌幅

REPH 简况

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
展开

Webull提供Recro Pharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。